


**DRUG INNOVATION
VENTURES AT EMORY
(DRIVE)**



DRIVE: An Independent Biotechnology Company Operating in an Innovative University Environment

- DRIVE, LLC is an independently managed biotechnology company, wholly owned by Emory University
- The Company was founded in 2012 and funded by a \$20M investment from Emory University
- DRIVE can form its own for-profit spin-outs to accommodate private investment, and can in- and out-license technologies
- The Company's research and development labs are housed in a 1100 sq. meters, state-of-the-art facility on the Yerkes National Primate Center site
- The Company currently has 30 employees and has the capability of advancing drugs candidates through Phase II clinical trials
- DRIVE has ready access to the intellectual and physical assets of a major research university

A Not-For-Profit Drug Development Company Focused on Viral Diseases of Global Concern



Our Focus: Developing Therapeutics to Treat RNA Viral Infections of Global Concern

- RNA viruses cause epidemic disease and are responsible for 80% of the viral disease burden worldwide. They are the major contributions to the pool of emerging and reemerging infectious diseases
- The vast majority of RNA viral disease is caused by two subgroups of RNA viruses, those carrying their genome as either negative (-) or positive (+) sense, single-stranded RNA
- There are no drugs available to prophylax against or treat infections due to the vast majority of these viruses. We are working to specifically address viruses in the following families:

(+) Single-Stranded RNA Viruses

Flaviviridae: HCV, Dengue, West Nile

Togaviridae: EEEV, VEEV, WEEV

Coronaviridae: SARs-like viruses, MERS – coronaviruses

(-) Single-Stranded RNA Viruses

Paramyxoviridae: Respiratory syncytial virus (RSV), Human parainfluenza viruses

Orthomyxoviridae: Influenza A & B

Bunyaviridae: Hantaviruses, Rift Valley fever virus

The DRIVE Proof of Concept: The Development of a Novel Antiviral Asset

- A novel series of ribonucleotide analogs was designed and synthesized in **June, 2013**
- In vitro efficacy and cytotoxicity profiles were determined in **August, 2013**
- Patents were filed in **September, 2013**
- Cellular metabolism studies were conducted in **October, 2013** and in vivo distribution and metabolism studies were completed in **November, 2013**
- Acute toxicity in rats was completed in **December, 2013**
- First meetings with potential partners were held at JP Morgan Conference in **January, 2014**
- A seven day dose-ranging toxicology study in rats was completed in **February, 2014**
- The out-licensing deal closed in **September, 2014** with an upfront payment. The deal includes additional milestone payments and a royalty on product sales.
- ***These funds will be reinvested in our R&D activities, thereby enabling DRIVE to attempt to address other unmet medical needs.***